Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Van Dyke Website

Terry A. Van Dyke, Ph.D.

Selected Publications

1)  Merlino G, Flaherty K, Acquavella N, Day C, Aplin A, Holmen S, Topalian S, Van Dyke T, Herlyn M.
Meeting report: The future of preclinical mouse models in melanoma treatment is now.
Pigment Cell Melanoma Res. [Epub ahead of print], 2013.
2)  Van Dyke T, Merlino G.
Beta-catenin in metastatic melanoma--the smoking gun reloaded.
Pigment Cell Melanoma Res. 25: 125-6, 2012.
3)  Yoon Y, Cowley D, Gallant J, Jones S, Van Dyke T, Rivera-Perez J.
Conditional Aurora A deficiency differentially affects early mouse embryo patterning.
Dev Biol. 371: 77-85, 2012.
4)  Szabova L, Yin C, Bupp S, Guerin TM, Schlomer JJ, Householder DB, Baran ML, Yi M, Song Y, Sun W, McDunn JE, Martin PL, Van Dyke T, Difilippantonio S.
Perturbation of Rb, p53 and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer.
Cancer Res. 72: 4141-53, 2012.
5)  Weaver Z, Difilippantonio S, Carretero J, Martin PL, El Meskini R, Iacovelli AJ, Gumprecht M, Kulaga A, Guerin T, Schlomer J, Baran M, Kozlov S, McCann T, Mena S, Alshahrour F, Alexander D, Wong K, Van Dyke T.
Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response.
Cancer Res. 72: 5921-5933, 2012.
6)  Serber DW, Rogala A, Makarem M, Rosson GB, Simin K, Godfrey V, Van Dyke T, Eaves CJ, Bultman SJ.
The BRG1 chromatin remodeler protects against ovarian cysts, uterine tumors, and mammary tumors in a lineage-specific manner.
PLoS ONE. 7: e31346, 2012.
7)  Lu X, Yang C, Yin C, Van Dyke T, Simin K.
Apoptosis is the essential target of selective pressure against p53, whereas loss of additional p53 functions facilitates carcinoma progression.
Mol. Cancer Res. 9: 430-9, 2011.
8)  Cook DR, Solski PA, Bultman SJ, Kauselmann G, Schoor M, Kuehn R, Friedman LS, Cowley DO, Van Dyke T, Yeh JJ, Johnson L, Der CJ.
The ect2 rho Guanine nucleotide exchange factor is essential for early mouse development and normal cell cytokinesis and migration.
Genes Cancer. 2: 932-42, 2011.
9)  Van Dyke T.
Finding the tumor copycat: approximating a human cancer.
Nat. Med. 16: 976-7, 2010.
10)  Walrath JC, Hawes JJ, Van Dyke T, Reilly KM.
Genetically engineered mouse models in cancer research.
Adv. Cancer Res. 106: 113-64, 2010.
Click Here to View Expanded Bibliography.

This page was last updated on 5/2/2013.